215 related articles for article (PubMed ID: 31849449)
1. Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma.
Yin Y; Guo J; Teng F; Yu L; Jiang Y; Xie K; Jiang M; Fang J
Drug Des Devel Ther; 2019; 13():4173-4184. PubMed ID: 31849449
[TBL] [Abstract][Full Text] [Related]
2. Ventilagolin Suppresses Migration, Invasion and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells by Downregulating Pim-1.
Liu Y; Cheng DH; Lai KD; Su H; Lu GS; Wang L; Lv JH
Drug Des Devel Ther; 2021; 15():4885-4899. PubMed ID: 34880599
[TBL] [Abstract][Full Text] [Related]
3. Chinese herbal formula QHF inhibits hepatocellular carcinoma metastasis via HGF/c-Met signaling pathway.
Yuan S; Gong Y; Chen R; Du J; Zhang H; Chen T
Biomed Pharmacother; 2020 Dec; 132():110867. PubMed ID: 33075668
[TBL] [Abstract][Full Text] [Related]
4. Chamaejasmenin E from Stellera chamaejasme induces apoptosis of hepatocellular carcinoma cells by targeting c-Met in vitro and in vivo.
Yu XQ; Yan QL; Shen S; Cheng ZY; Huang XX; Yao GD; Song SJ
Bioorg Chem; 2022 Feb; 119():105509. PubMed ID: 34844768
[TBL] [Abstract][Full Text] [Related]
5. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
6. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
7. Anisodamine Suppressed the Growth of Hepatocellular Carcinoma Cells, Induced Apoptosis and Regulated the Levels of Inflammatory Factors by Inhibiting NLRP3 Inflammasome Activation.
Li P; Liu Y; He Q
Drug Des Devel Ther; 2020; 14():1609-1620. PubMed ID: 32425506
[TBL] [Abstract][Full Text] [Related]
8. I
Wu L; Sun B; Lin X; Liu C; Qian H; Chen L; Yang Y; Shen F; Su C
Genes Cells; 2018 Jan; 23(1):35-45. PubMed ID: 29210217
[TBL] [Abstract][Full Text] [Related]
9. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
10. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.
Merchant M; Ma X; Maun HR; Zheng Z; Peng J; Romero M; Huang A; Yang NY; Nishimura M; Greve J; Santell L; Zhang YW; Su Y; Kaufman DW; Billeci KL; Mai E; Moffat B; Lim A; Duenas ET; Phillips HS; Xiang H; Young JC; Vande Woude GF; Dennis MS; Reilly DE; Schwall RH; Starovasnik MA; Lazarus RA; Yansura DG
Proc Natl Acad Sci U S A; 2013 Aug; 110(32):E2987-96. PubMed ID: 23882082
[TBL] [Abstract][Full Text] [Related]
11. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
Xiang Q; Zhen Z; Deng DY; Wang J; Chen Y; Li J; Zhang Y; Wang F; Chen N; Chen H; Chen Y
J Exp Clin Cancer Res; 2015 Oct; 34():118. PubMed ID: 26458953
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol suppresses human hepatocellular carcinoma via targeting HGF-c-Met signaling pathway.
Gao F; Deng G; Liu W; Zhou K; Li M
Oncol Rep; 2017 Feb; 37(2):1203-1211. PubMed ID: 28075467
[TBL] [Abstract][Full Text] [Related]
14. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
Huang X; Gan G; Wang X; Xu T; Xie W
Autophagy; 2019 Jul; 15(7):1258-1279. PubMed ID: 30786811
[TBL] [Abstract][Full Text] [Related]
15. A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth.
Luo T; Zhang SG; Zhu LF; Zhang FX; Li W; Zhao K; Wen XX; Yu M; Zhan YQ; Chen H; Ge CH; Gao HY; Wang L; Yang XM; Li CY
J Exp Clin Cancer Res; 2019 Mar; 38(1):130. PubMed ID: 30885237
[TBL] [Abstract][Full Text] [Related]
16. Madecassoside suppresses proliferation and invasiveness of HGF-induced human hepatocellular carcinoma cells via PKC-cMET-ERK1/2-COX-2-PGE2 pathway.
Li Z; You K; Li J; Wang Y; Xu H; Gao B; Wang J
Int Immunopharmacol; 2016 Apr; 33():24-32. PubMed ID: 26851630
[TBL] [Abstract][Full Text] [Related]
17. Anti-neoplastic Effect of Ginkgolide C through Modulating c-Met Phosphorylation in Hepatocellular Carcinoma Cells.
Yang MH; Baek SH; Um JY; Ahn KS
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167504
[TBL] [Abstract][Full Text] [Related]
18. Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways.
Wu JR; Hu CT; You RI; Ma PL; Pan SM; Lee MC; Wu WS
PLoS One; 2015; 10(1):e0114495. PubMed ID: 25607934
[TBL] [Abstract][Full Text] [Related]
19. Isomalto oligosaccharide sulfate inhibits tumor growth and metastasis of hepatocellular carcinoma in nude mice.
Xiao CL; Tao ZH; Guo L; Li WW; Wan JL; Sun HC; Wang L; Tang ZY; Fan J; Wu WZ
BMC Cancer; 2011 Apr; 11():150. PubMed ID: 21513518
[TBL] [Abstract][Full Text] [Related]
20. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma.
Yang C; Qin S
Cancer Med; 2018 Sep; 7(9):4570-4583. PubMed ID: 30109780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]